2018年糖尿病重要临床进展回顾
|
摘要
2018年,美国糖尿病学会(ADA)、欧洲糖尿病研究协会(EASD)、中华医学会糖尿病学分会(CDS)、中国老年医学学会(CGS)及中国微循环学会(CSM)等组织就糖尿病及其并发症发布一系列指南和共识,关于糖尿病分级预防、糖尿病诊断标准、糖尿病患者血压血脂要求、糖尿病患者综合管理、降糖药物的疗效和不良反应等有新的建议和推荐。上述内容对糖尿病的预防、诊断、治疗及糖尿病后续研究都具有重要和深远的意义,对此进行综述。
In 2018, American Diabetes Association(ADA), European Association for the Study of Diabetes(EASD), Chinese Diabetes Society(CDS), Chinese Geriatrics Society(CGS) and Chinese Society of Microcirculation(CSM), etc. published several guidelines and statements on diabetes and its complications. The prevention of diabetes, diagnostic criteria of diabetes, the characteristics of blood pressure and blood lipid, integrated management of diabetes, the efficacy and adverse reaction of hypoglycemic drugs were also suggested and recommended. These guidelines and statements play key roles in the prevention, diagnosis, treatment and future research of diabetes mellitus, which is reviewed in this article.
In 2018, American Diabetes Association(ADA), European Association for the Study of Diabetes(EASD), Chinese Diabetes Society(CDS), Chinese Geriatrics Society(CGS) and Chinese Society of Microcirculation(CSM), etc. published several guidelines and statements on diabetes and its complications. The prevention of diabetes, diagnostic criteria of diabetes, the characteristics of blood pressure and blood lipid, integrated management of diabetes, the efficacy and adverse reaction of hypoglycemic drugs were also suggested and recommended. These guidelines and statements play key roles in the prevention, diagnosis, treatment and future research of diabetes mellitus, which is reviewed in this article.
引文
[1]American Diabetes Association.Standards of medical care in diabetes-2018[J].Diabetes care,2018,41(Suppl 1):S1-S159
[2]Chiang JL,Maahs DM,Garvey KC,et al.Type 1 diabetes in children and adolescents:a position statement by the American Diabetes Association[J].Diabetes Care,2018,41(9):2026-2044.
[3]Dav ies M J,D’A lessio DA,Frad k in J,et al.Management of hyperglycaemia in type 2 diabetes,2018.A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J].Diabetologia,2018,61(12):2461-2498.
[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
[5]中国老年糖尿病诊疗措施专家共识编写组.中国老年2型糖尿病诊疗措施专家共识(2018年版)[J].中华内科杂志,201857(9):626-641.
[6]中华医学会糖尿病学分会视网膜病变学组.糖尿病视网膜病变防治专家共识[J].中华糖尿病杂志,2018,10(4):241-247.
[7]中国微循环学会周围血管疾病专业委员会糖尿病足学组.糖尿病足创面修复治疗专家共识[J].中华糖尿病杂志,201810(5):305-309.
[8]ASCEND Study Collaborative Group.Effects of aspirin for primary prevention in persons with diabetes mellitus[J].New Engl J Med2018,379(16):1529-1539.
[9]Ryan PB,Buse JB,Schuemie MJ,et al.Comparative effectiveness of canagliflozin,SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus:a real-world meta-analysis of 4 observational databases(OBSERVE-4D)[J].Diabetes Obesity Metab,2018,20(11):2585-2597.
[10]Neal B,Perkov ic V,Mahaf fey KW,et al.Canaglif lozin and cardiovascular and renal events in type 2 diabetes[J].New Engl J Med2017,377(7):644-657.
[11]Bjerregaard LG,Jensen BW,?ngquist L,et al.Change in overweight from childhood to early adulthood and risk of type 2 diabetes[J].New Engl J Med,2018,378(14):1302-1312.
[12]Penno G,Solini A,Orsi E,et al.Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes:The renal insufficiency and cardiovascular events(RIACE)italian multicentre study[J].Diabetologia,2018,61(11):2277-2289.
[13]Amod A,Emerson SS,Marso SP,et al.Chronic kidney disease(CKD)and risk of mortality,cardiovascular(CV)events,and severe hypoglycemia in type 2 diabetes(T2D)-DEVOTE results[J].Diabetes2018,67(Suppl 1):530.
[14]U.S.Food and Drug Administration.FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes[EB/OL].[2019-01-02][2018-08-29].https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm.
[15]U.S.Food and Drug Administration.Guardian connect systemP160007[EB/OL].(2018-03-08)[2019-01-02].https://www fda.gov/MedicalDev ices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm604253.htm.
[2]Chiang JL,Maahs DM,Garvey KC,et al.Type 1 diabetes in children and adolescents:a position statement by the American Diabetes Association[J].Diabetes Care,2018,41(9):2026-2044.
[3]Dav ies M J,D’A lessio DA,Frad k in J,et al.Management of hyperglycaemia in type 2 diabetes,2018.A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J].Diabetologia,2018,61(12):2461-2498.
[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
[5]中国老年糖尿病诊疗措施专家共识编写组.中国老年2型糖尿病诊疗措施专家共识(2018年版)[J].中华内科杂志,201857(9):626-641.
[6]中华医学会糖尿病学分会视网膜病变学组.糖尿病视网膜病变防治专家共识[J].中华糖尿病杂志,2018,10(4):241-247.
[7]中国微循环学会周围血管疾病专业委员会糖尿病足学组.糖尿病足创面修复治疗专家共识[J].中华糖尿病杂志,201810(5):305-309.
[8]ASCEND Study Collaborative Group.Effects of aspirin for primary prevention in persons with diabetes mellitus[J].New Engl J Med2018,379(16):1529-1539.
[9]Ryan PB,Buse JB,Schuemie MJ,et al.Comparative effectiveness of canagliflozin,SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus:a real-world meta-analysis of 4 observational databases(OBSERVE-4D)[J].Diabetes Obesity Metab,2018,20(11):2585-2597.
[10]Neal B,Perkov ic V,Mahaf fey KW,et al.Canaglif lozin and cardiovascular and renal events in type 2 diabetes[J].New Engl J Med2017,377(7):644-657.
[11]Bjerregaard LG,Jensen BW,?ngquist L,et al.Change in overweight from childhood to early adulthood and risk of type 2 diabetes[J].New Engl J Med,2018,378(14):1302-1312.
[12]Penno G,Solini A,Orsi E,et al.Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes:The renal insufficiency and cardiovascular events(RIACE)italian multicentre study[J].Diabetologia,2018,61(11):2277-2289.
[13]Amod A,Emerson SS,Marso SP,et al.Chronic kidney disease(CKD)and risk of mortality,cardiovascular(CV)events,and severe hypoglycemia in type 2 diabetes(T2D)-DEVOTE results[J].Diabetes2018,67(Suppl 1):530.
[14]U.S.Food and Drug Administration.FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes[EB/OL].[2019-01-02][2018-08-29].https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm.
[15]U.S.Food and Drug Administration.Guardian connect systemP160007[EB/OL].(2018-03-08)[2019-01-02].https://www fda.gov/MedicalDev ices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm604253.htm.